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Summary 
Nuclear hormone receptors comprise a superfamily of 
ligand-modulated transcription factors that mediate 
the transcriptional activities of steroids, retinoids, and 
thyroid hormones. A growing number of related pro- 
teins have been identified that possess the structural 
features of hormone receptors, but that lack known 
ligands. Known as orphan receptors, these proteins 
represent targets for novel signaling molecules. We 
have isolated a mammalian orphan receptor that forms 
a heterodimeric complex with the retinoid X receptor. 
A screen of candidate ligands identified farnesol and 
related metabolites as effective activators of this com- 
plex. Farnesol metabolites are generated intracellu- 
larly and are required for the synthesis of cholesterol, 
bile acids, steroids, retinoids, and farnesylated pro- 
teins. Intermediary metabolites have been recognized 
as transcriptional regulators in bacteria and yeast. Our 
results now suggest that metabolite-controlled intra- 
cellular signaling systems are utilized by higher or- 
ganisms. 
*Present Address: Department ofMedicine, The Johns Hopkins Hospi- 
tal, Baltimore, Maryland 21287. 
Introduction 
Molecular cloning studies have demonstrated that recep- 
tors for steroid, retinoid, vitamin D, and thyroid hormones 
comprise a superfamily of regulatory proteins that are 
structurally and functionally related (Evans, 1988; Leid et 
al., 1992a). Known as nuclear hormone receptors, these 
proteins bind to cis-acting elements in the promoters of 
their target genes and modulate gene expression in re- 
sponse to hormone. Nuclear receptors can be classified 
based on their DNA-binding properties (Evans, 1988; 
Glass, 1994). The glucocorticoid, estrogen, androgen, 
progestin, and mineralocorticoid receptors bind as homo- 
dimers to hormone response elements organized as in- 
verted repeats (Glass, 1994). A second class of receptors, 
including the retinoic acid receptor (RAR), the thyroid hor- 
mone receptor (T3 R), the vitamin D3 receptor, the fatty acid/ 
peroxisome proliferator-activated receptor (PPAR), and the 
ecdysone receptor (EcR), bind as heterodimers with a com- 
mon partner, retinoid X receptor (RXR) (Yu et al., 1991 ;Hal- 
lenbeck et al., 1992; Kliewer et al., 1992; Leid et al., 1992b; 
Marks et al., 1992; Zhang et al., 1992), the 9-cis retinoic 
acid receptor (Heyman et al., 1992; Levin et al., 1992). 
An important advance in the characterization of this su- 
perfamily of regulatory proteins has been the delineation 
of a growing number of gene products (orphan receptors) 
that possess the structural features of hormone receptors, 
but that lack known ligands. The search for hormonal acti- 
vators for these newly discovered orphan receptors has 
created exciting areas of research on previously unknown 
signaling pathways (Issemann and Green, 1990; Heyman 
et al., 1992; Levin et al., 1992). The ability to identify novel 
hormonal systems has important implications in physiol- 
ogy as well as human disease and its treatment. 
As receptors have been identified for all known nuclear- 
acting hormones, a question arises as to the types of mole- 
cules that may activate orphan receptors. Products of in- 
termediary metabolism act as transcriptional regulators in 
bacteria and yeast, suggesting that they may serve similar 
functions in higher organisms (Tomkins, 1975; O'Malley, 
1989). A crucial biosynthetic pathway in higher eukaryotes 
is the mevatonate pathway, which leads to the synthesis 
of cholesterol, bile acids, porphyrin, dolichol, ubiquinone, 
carotenoids, retinoids, vitamin D, steroid hormones, and 
farnesylated proteins. The farnesol derivative, farnesyl py- 
rophosphate, is a key metabolic intermediate, since it is 
the last precursor common to all branches of the mevalo- 
nate pathway (Goldstein and Brown, 1990). We describe 
an orphan nuclear receptor named farnesoid X-activated 
receptor (FXR) that is activated by farnesol and related 
molecules. FXR provides an example of a vertebrate tran- 
scription factor that is regulated by an intracellular metabo- 
lite and suggests the existence of a potentially novel verte- 
brate-signaling pathway. 
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Figure 1. FXR Is a Member of the Nuclear Receptor Superfamily 
(A) The nucleotide and amino acid sequence of rat FXR. The 2.1 kb 
cDNA encodes a 469 amino acid open reading frame (ORF). The ORF 
begins with an initiation codon that appears eight codons downstream 
of an in-frame stop codon and ends with a TGA stop codon (asterisk). 
In vitro translation of FXR-derived RNA results in a protein with a 
relative molecular mass (M,) of 54,000, close to the predicted Mr of 
53,934 (data not shown). Amino acids comprising the conserved DBD 
(Cys-124-Met-189) are in white letters on black background. The LBD 
(Leu-250-GIn-469) is boxed. The FXRal cDNA contains a short inter- 
spersed repetitive DNA element (Sutcliffe et al., 1984) in the 3' untrans- 
lated region followed by a polyadenylation signal. 
(B) Amino acid sequence comparison between rat FXR and Drosophila 
EcR. Similarity between the DBDs and LBDs is schematically repre- 
sented as percent amino acid identity. Amino acid regions comprising 
each domain are numbered accordingly. 
Results and Discussion 
Receptor Gene Isolation 
A degenerate ol igonucleotide probe corresponding to the 
highly conserved P box/DNA recogn!tion helix (TCEGCK 
(GN)FF) of the nuclear receptor superfamily DNA-binding 
domain (DBD) was used to isolate a cDNA for FXR from 
rat liver (Figure 1A). A similar cDNA has recently been 
cloned from mouse liver (Seol et al., 1995). Examination 
of the amino acid sequence of FXR reveals that it is a 
member of the nuclear receptor superfamily (Evans, 1988) 
and is most closely related to the insect EcR (Koelle et 
al., 1991). FXR and EcR share 81% amino acid identity 
within their DBDs (Figure 1B). The carboxy-terminal i- 
gand-binding domain (LBD) is a complex region encoding 
subdomains for ligand binding, dimerization, and tran- 
scriptional activation (Forman and Samuels, 1990; Glass, 
1994). FXR and EcR LBDs exhibit 34% sequence identity 
(59% similarity) throughout the LBD (Figure 1B). Closer 
inspection reveals that similarity is highest within the hep- 
tad repeats required for receptor dimerization (Forman 
and Samuels, 1990). 
FXR-RXR Complexes Bind DNA 
Previous studies have shown that the physiologically ac- 
tive form of EcR is an EcR-ultraspiracle (EcR-usp) hetero- 
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Figure 2. FXR and RXR Interact in Cells and In Vitro 
(A) The LBDs of FXR and RXR(I interact specifically in cells. CV-1 
cells were transiently transfected, as indicated, with CMV promoter- 
driven expression vectors (100 ng per 10 ~ cells) containing the yeast 
GAL4 DBD alone (GAL411-147]), GAL4 linked to the FXR LBD (GAL4- 
FXR[181-469]), the 78 amino acid herpesvirus VP16 transactivation 
domain alone (data not shown), or the VP16 domain linked to the 
amino-terminal end of the LBDs for human RXR(~ (VP-RXR[203-462]), 
mouse PPARa (VP-PPAR[155-468]), human vitamin D receptor 
(VDR) (VP-VDR[92-427]), human T3R~ (VP-T3R[173-456]), or human 
RAR~ (VP-RAR[156-462]). All cells were cotransfected with a thymi- 
dine kinase (TK)-Iuciferase reporter construct (300 ng per 105 cells) 
containing four copies of the yeast GAL4 upstream activating se- 
quence and a CMV-driven 13-galactosidase expression vector (500 ng/ 
105 cells) as internal control. The only combination resulting in signifi- 
cant activation was GAL4-FXR plus VP-RXR. As expected from previ- 
ous in vitro studies (Yu et al., 1991; Hallenbeck et al., 1992; Kliewer 
et al., 1992; Leid et al., 1992b; Marks et al., 1992; Zhang et al., 1992), 
VP-PPAR, VP-VDR, VP-T3R, and VP-RAR interacted productively 
with GAL4-RXR (K. Umesono, personal communication; R. M. E, un- 
published data), indicating that these VP16 chimeras are functionally 
expressed. 
(B) FXR and RXR bind cooperatively to DNA. Mobility shift experiments 
were performed using the indicated 32P-labeled DNA probes. Each 
probe is flanked by Hindlll overhangs. Their sequences are as follows 
(Yao et al., 1992): hsp27-EcRE, GGTTCA A TGCACT; EcRE= (11 N- 
hsp27-EcRE), C_GI-FCA A TGCACA__; IR-1, AGGTCA A TGACCT; 
IR-lm, AGAACA A TGTTCT. The position of mutations introduced into 
the hsp27-EcRE and the idealized IR-1 are underlined above and 
indicated in the figure (X). The gel was autoradiographed for 1.5 hr 
with an intensifying screen. 
dimer (usp is a Drosophila homolog of RXR) (Thomas et 
al., 1993; Yao et al., 1993). This prompted us to examine 
whether FXR also interacts with RXR. To do so, we made 
use of a two-hybrid system modified for use in mammal ian 
cells (Nagpal et al., 1993). The LBD/dimerization domain 
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of FXR was fused to the yeast GAL4 DBD (GAL4-FXR). 
As seen in Figure 2A, the GAL4 DBD or the GAL4-FXR 
chimera is incapable of stimulating transcription from a 
reporter construct containing the GAL4 upstream activat- 
ing sequence. Similarly, a fusion protein containing the 
herpesvirus VP16 transactivation domain linked to the 
RXRa LBD (VP-RXR) is inactive when expressed alone 
or with the GAL4 DBD (Figure 2A). However, when GAL4- 
FXR and VP-RXR are coexpressed, the reporter is acti- 
vated 500-fold, indicating that FXR and RXRa interact ef- 
ficiently in cells (Figure 2A). No interaction could be 
detected between FXR and other nuclear hormone recep- 
tors, indicating that FXR and RXR~ associate in a highly 
specific fashion. 
The amino acids comprising the DNA recognition helix 
(P box, Cys-141-Lys-145) of FXR and EcR are identical, 
suggesting that the FXR-RXR~ complex could recognize 
an ecdysone response element (EcRE): Electrophoretic 
mobility shift analysis was performed using ~P-labeled 
DNA and in vitro translated FXR and RXRm As seen in 
Figure 2B, neither FXR nor RXR~ was capable of high 
affinity binding to the hsp27-EcRE. However, when 
mixed, the two proteins bind cooperatively. Binding is spe- 
cific, as indicated by the inability of the FXR-RXR complex 
to recognize the mutated EcRE (EcREm). The hsp27- 
EcRE consists of two imperfect core-binding sites ar- 
ranged as inverted repeats separated by 1 nt (IR-1). Ac- 
cordingly, the binding of FXR-RXR was further examined 
on an idealized IR-1 containing two consensus half-sites. 
As seen in Figure 2B, the FXR-RXR complex bound coop- 
eratively to the idealized IR-1, but not to a mutant IR-1 
containing substitutions within the half-sites (IR-lm). 
Activation by Farnesoids 
We sought to determine whether FXR possessed tran- 
scriptional activity that could be hormonally controlled. 
Based on the identification of an EcRE as a DNA target, 
a reporter plasmid was constructed containing five copies 
of the hsp27 response element linked to a truncated 
mouse mammary tumor virus promoter (Yao et al., 1993). 
This reporter was cotransfected into CV-1 cells alone or 
with expression vectors for FXR, RXR~, or both. Cotrans- 
fected cells were treated with a variety of potential ligands 
and monitored for changes in luciferase activity. Candi- 
date ligands or activators (or both) included a variety of 
low molecular weight molecules that have been reported 
to have specific biological activity. Unexpectedly, juvenile 
hormone III (JH III) (Moore, 1990) (50 I~M) elicited a strong 
induction (10-fold) of luciferase activity in cells expressing 
both FXR and RXR (Figure 3A). Other potential igands, 
including steroids, retroretinoids, eicosanoids, and bile 
acids, had no effect. JH III appears to be specific for the 
FXR-RXR~ complex, since it failed to activate EcR-usp, 
RXR, T3R, or RAR (Figure 3B). 
Although JH III activates FXR-RXR, it fails to activate 
either FXR or RXR alone (Figures 3A and 3B). This is 
reminiscent of the Drosophila EcR, which requires RXR/ 
usp for transcriptional activity (Yao et al., 1992, 1993; 
Thomas et al., 1993). EcR itself binds ecdysteroids with 
low affinity (Yao et al., 1993); high affinity binding and 
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Figure 3. Hormonally Controlled Activity of FXR-RXR 
(A) JH III activates FXR-RXR heterodimers. CV-1 cells were transiently 
transfected with hsp27-EcRE x 5 ,'~ MTV-luciferase (1000 ng per 105 
cells) alone (minus ign) or with expression vectors for rat FXR, human 
RXRa, or both (50 ng per 10 s cells). Reporter activity was assayed 
after treating cells with or without 50 p.M JH Ill (cis- 10,11 -epoxy-3,7,11 - 
trimethyl-trans-trans-2,6-dodecadienoic acid methyl ester). JH III failed 
to activate FXR-RXR complexes using the parental AMTV reporter 
construct that lacked the EcREs (data not shown). 
(B) JH III fails to activate other nuclear eceptors. The activity of the 
following receptor/luciferase reporter pairs was assayed in the pres- 
ence of 50 pM JH III or the indicated receptor-specific ligand: Drosoph- 
ila G-EcR-usp/hsp27-EcRE x5 ~MTV (1000 ng per 105 cells), human 
RXR~dCRBPII-TK, human T3RI~/TREpx2-TK, and human RARe./ 
DR5 x 2-TK. TK-reporter constructs (300 ng per 105 cells) and CMV- 
driven receptor expression vectors (100 ng per 10 s cells) were added 
as indicated. 
(C) FXR-RXR is synergistically activated by JH III and LG69. CV-1 
cells were transiently transfected as in (A), but treated without or with 
50 I~M JH III, 100 nM LG69, and JH III plus LG69. Datapoints were 
normalized for differences in transfection efficiency and plotted as 
relative activity where the untreated reporter is defined to have an 
activity of 1 U. 
subsequent transcriptional activation require coexpres- 
sion of EcR with RXR/usp. Thus, while the EcR-RXR/ 
usp heterodimer is the physiologically active complex, the 
ability to respond to ecdysone is determined by the EcR 
component of the complex. Since the EcR-RXR hetero- 
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Figure 4. Profiles of FXR-RXR Activity Using Various Isoprenoids 
(A) Activation of FXR-RXR by various farnesol metabolites. CV-1 cells 
were transiently transfected as in Figure 3A with expression vectors 
for rat FXR and hu man RXRm Cells were treated with 50 I~M concentra- 
tions of each compound. Similar esults were obtained with all-trans 
and mixed isomers of farnesol and farnesoic acid. Data are plotted 
as fold activation relative to untreated cells. Transfections were per- 
formed as described in Figure 3. Farnesoic acid was synthesized as 
described above (Kulkarni et al., 1987). 
(B) Dose response profile. The experiment was performed as in (A) 
with the indicated concentration fJH III and farnesol (mixed isomers). 
dimer is composed of two functional receptors, the com- 
plex can be activated independently by ecdysteroids or 
9-cis RA and can be activated synergistically by both li- 
gands (Thomas et al., 1993). The structural and functional 
similarities between EcR and FXR prompted us to exam- 
ine whether the FXR-RXR complex could also be syner- 
gistically activated by JH Ill and the RXR-specific ligand 
LG69 (Kurokawa et al., 1994). Using the hsp27-EcRE re- 
porter (Figure 3C), we activated the FXR-RXR~ complex 
17-fold by 50 I~M JH Ill, 76-fold by 100 nM LG69, and 
212-fold bythe combination of JH III and LG69. This syner- 
gistic activity required coexpression of FXR with RXR~ 
(Figure 3C), RXRI], or RXR~, (data not shown). The ability 
of J H III to synergize with saturating doses of LG69 or 9-cis 
RA (data not shown) suggests that these two compounds 
have distinct targets within the FXR-RXR complex. As 
LG69 is thought to be an RXR-specific ligand (Kurokawa 
et al., 1994), these results imply that JH III responsiveness 
is determined by the FXR component of the FXR-RXR 
complex. 
JH III is a metabolic derivative of farnesyl pyrophos- 
phate, a key precursor in the mevalonate biosynthetic 
pathway (Goldstein and Brown, 1990). Accordingly, we 
decided to test whether metabolites derived from the mev- 
alonate pathway in mammalian cells could also serve as 
activators of the FXR-RXRa complex. Indeed, farnesol 
(trans-trans or mixed isomers, 50 ~.M) served as a strong 
activator of FXR-RXRa (Figure 4A), whereas other fame- 
soids such as farnesal, farnesyl acetate, and geranylgera- 
niol possessed weaker activity. In contrast, little or no acti- 
vation was seen with 50 p.M concentrations of geraniol, 
farnesoic acid, squalene (Figure 4A), methoprene, meva- 
Ionate, squalene epoxide, squalene dioxide, lanosterol, 
24,25-epoxycholesterol, pregnenalone, dehydroepian- 
drosterone, bile acids, or 10 I~M 25-hydroxycholesterol 
(data not shown). Mevalonate (200 ~M) displayed weak 
activity, provided cells were cotransfected with a mevalo- 
nate transporter protein (Kim et al., 1992; data not shown). 
Since FXR-RXR is not activated by potent JH analogs 
(methoprene; data not shown) and since the JH receptor 
has not been identified, it remains unclear what relation- 
ship, if any, exists between FXR and the putative insect 
receptor for JH. 
Activation of classical nuclear receptors occurs at physi- 
ological concentrations of circulating hormones. To be rel- 
evant, activation of FXR should occur at physiologic fame- 
soid concentrations. The levels of endogenous farnesoids 
have been difficult o determine, owing to their rapid me- 
tabolism and potential sequestration by intracellular and 
extracellular binding proteins. However, intracellular con- 
centrations may be inferred from the Michaelis constant of 
enzymes that utilize isoprenoid substrates. These values 
have been reported to be in the range of 0.5-10 I~M for 
protein farnesyltransferase and isopentenyl pyrophos- 
phate isomerase (Rilling and Chayet, 1985; Reiss et al., 
1990; Gomez et al., 1993). Furthermore, down-regulation 
of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase ac- 
tivity by a mevalonate-derived nonsterol occurs when mev- 
alonate is added to cells at concentrations in excess of 100 
I~M (Brown and Goldstein, 1980; Nakanishi et al., 1988). 
Together, these reports suggest that physiologic concen- 
trations of farnesoids are in the micromolar ange. Accord- 
ingly, dose response studies were performed using in- 
creasing concentrations of farnesol and JH III, the two 
most effective FXR-RXR activators (Figure 4B). Activation 
of FXR-RXR required concentrations of 5-50 t~M, sug- 
gesting that FXR-RXR activity is regulated at appropriate 
concentrations. Similarly, regulation of PPAR and sterol- 
regulatory element-binding protein 1 (SREBP-1) is known 
to require 5-100 I~M doses of fatty acids (Green and Wahli, 
1994) or cholesterol (Wang et al., 1994), levels that are 
consistent with the presumed intracellular concentrations 
of these compounds. 
Expression of FXR mRNA in 
Isoprenoidogenic Tissues 
One expectation of an intracellular metabolic activator is 
that it would be synthesized in the same tissues in which 
its receptor is expressed, Northern blot analysis revealed 
restricted expression of a 2,3 kb FXR-specific transcript 
in liver and kidney (Figure 5). In situ hybridization and 
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Figure 5. Expression of FXR mRNA 
Northern blot analysis of rat tissues. The source of the poly(A) ÷ RNA 
is shown above ach lane. Muscle refers to skeletal muscle. 
histochemistry (Figure 6) indicated that FXR expression 
is limited to the liver, kidney, and gut of rat embryonic 
day 19.5 (E19.5) embryo sections (Figure 6A). Background 
levels were seen in other tissues and in experiments using 
a control probe (Figure 6B). As expected (Mangelsdorf et 
al., 1992), mRNA for the heterodimerizing partner RXRI3 
is also found in the liver, kidney, and gut, as well as other 
embryonic tissues (Figure 6C). FXR expression in the gut 
is prominent in the intestinal villi (Figures 6D-6G). In the 
E19.5 kidney, highest levels of expression occur in the 
renal tubules (Figures 6D-6G). In the adult rat kidney, FXR 
is expressed in areas rich in renal tubules: the medullary 
rays and medullary stripe (Figure 6H). FXR expression is 
also detected in the adrenal cortex of the adult mouse 
(Figure 61). Thus, FXR expression is restricted to the liver, 
gut, adrenal gland, and kidney: tissues known to have 
significant flux through the mevalonate pathway (Edmond 
et al., 1976; Righetti et al., 1976; Wiley et al., 1977). 
Metabo l i c  In termed ia tes  as T ranscr ip t iona l  
Act ivators  
Our results identify an orphan nuclear receptor that is acti- 
vated by farnesol derivatives. A question that remains 
unanswered is the mechanism by which farnesoids acti- 
vate FXR. One possibility is that farnesoid treatment re- 
sults in the prenylation of FXR. This seems unlikely, since 
FXR lacks a known prenylation sequence (Moores et al., 
1991; Khosravi-Far et al., 1992) and is not prenylated by 
an in vitro prenyltransferase system (Khosravi-Far et al., 
1992; data not shown). Alternatively, JH III or farnesol (or 
both) could potentially serve as ligands for FXR. To date, 
we have not been able to demonstrate specific binding of 
JH III or farnesol (or both) to the FXR-RXR complex. Thus, 
a more likely possibility is that a farnesoid, farnesoid me- 
tabolite, or farnesoid-induced metabolite may serve as an 
authentic ligand for FXR. This is conceptually similar to 
the activation of RXR by all-trans RA and ultimately 
leads to the identification of retinoid X as 9-cis RA (Man- 
gelsdorf et al., 1990; Heyman et al., 1992; Levin et al., 
1992). 
The demonstration that FXR-RXR is regulated by fame- 
sold derivatives provides an example of gene regulation 
by intracellular metabolites. Other examples include the 
PPAR, a fatty acid-activated orphan receptor (Gottlicher 
et al., 1992) that regulates genes involved in fatty acid 
metabolism (Green and Wahli, 1994), and adipocyte differ- 
entiation (Tontonoz et al., 1994). Similarly, the low density 
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Figure 6. In Situ Hybridization and Histochemistry 
Antisense cRNA probes from the truncated mouse FXR cDNA or full- 
length mouse RXR~ cDNA were used as indicated. Control represents 
a truncated rat glucocorticoid receptor sense cRNA probe. (A)-(C) 
represent serial sagittal sections from an E19.5 rat embryo. Areas of 
positive hybridization appear white. (D) and (E), respectively, are bright 
(Nissl) and dark-field photomicrographs of the boxed region i  (C), 
hybridized with a FXR antisense probe. Similarly, (F) and (G) are de- 
rived from the boxed region in (D). (H) is a section from an adult rat 
(9-week old) kidney. The control probe revealed near-background hy- 
bridization (data not shown). (I) contains adult mouse (8-week old) 
adrenal gland and adjacent renal cortex and liver. Abbreviations: L,
liver; G, gut; K, kidney; P, pancreas. Scale bars: (A-C) 4 mm; (D-E) 
1 ram; (F-G) 0.3 ram; (H-I) 2 mm. Sections were apposed to Kodak 
X-OMAT film for 10 days (A-C and H-J) and then coated with nuclear 
emulsion (D-G) and exposed for 16 weeks. 
lipoprotein receptor gene regulator SREBP-1 is main- 
tained in an inactive form by cholesterol (Wang et al., 
1994). As with PPAR and SREBP-1, the FXR ligand, as 
well as FXR target genes, remains to be identified. None- 
theless, these regulatory systems define a novel paradigm 
of metabolite-controlled intracellular signaling in verte- 
brates (O'Malley, 1989). Such signaling provides a means 
to regulate responses to intracellular metabolites in a cell- 
autonomous fashion. By transducing metabolic ues into 
genomic responses, FXR, PPAR, and SREBP-1 may pro- 
vide examples for the metabolic code proposed by Tom- 
kins (1975). 
Experimental Procedures 
cDNA Isolation 
A degenerate 29-mer consensus oligonucleotide (5'-ACC TGT GAG 
GGC TGC AAR GKY FrC TTC AA 3'-) corresponding to the highly 
conserved P box/DNA recognition helix (TCEGCK(G/V)FF) of the nu- 
clear receptor superfamily DBD was used to probe a ~.gt11 mouse 
hepatoma Hepa-lclc7 cDNA library under low stringency conditions 
(Issemann and Green, 1990). An incomplete 850 bp mouse FXR cDNA 
clone was obtained. This clone was subsequently used to screen a 
regenerating rat liver cDNA library. The FXRal clone was obtained 
from this creen and sequenced by the dideoxy sequencing method. 
Cell 
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Cell Culture and Tranefection 
CV-1 cells were grown in DMEM supplemented with 10% AGI-X8 
resin-charcoal-stripped calf bovine serum, 50 U/ml penicillin G, and 
50 lig/ml streptomycin sulfate (DMEM-CBS) at 37°C in 50/o CO2. Cells 
were plated to 50%-80% confluence 1 day prior to transfection using 
phenol red-free DMEM with 10%o resin-charcoal-stripped fetal bovine 
serum (DMEM-FBS). Cells were transfected by lipofection using N-[1- 
(2,3-dioleoyloxy)propyl]-N,N,N-ammonium methyl sulfate (DOTAP) 
according to the instructions of the manufacturer (Boehringer Mann- 
helm). Reporter constructs (300-1000 ng per 10 s cells), cytomegalovi- 
rus (CMV)-driven receptor (50-100 ng per 105 cells), and IB-galacto- 
sidase expression vectors (500 ng per 105 cells) were added as 
indicated. After 2 hr, the liposomes were removed, and cells were 
treated for 40 hr with phenol red-free DMEM-FBS containing the indi- 
cated compounds: 50 p.M JH III, 100 nM muristerone A, 100 nM 9-cis 
RA, 100 nM "1"3 (L-triiodothyronine), 1 llM trans RA (all-trans RA), or 
100 nM LG69 (4-II-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-na p- 
thyl)-l-ethenyllbenzoic acid). Cells were harvested and assayed for 
luciferase and ~-galactosidase activity. All points were performed in 
triplicate and varied by less than 10%. Experiments were repeated 
three or more times with similar results. 
Electrophoretic Mobility Shift Assays 
Electrophoretic mobility shift assays were performed using proteins 
translated in a rabbit reticulocyte lysate system (TNT; Promega). Pro- 
teins (1 p.I) were incubated for 20 rain at room temperature with 100,000 
cpm of Klenow-labeled probes in 10 mM Tris (pH 6.0), 100 rnM KCI, 
60/0 glycerol, 0.05% NP-40, 1 rnM DTT, 100 ng/id poly(dl, dC) and then 
electrophoresed through a 50/o polyacrylamide gel in 0.5x TBE (45 
mM Tris base, 45 mM boric acid, 1 mM EDTA). 
RNA Expression Studies 
For Northern blot analysis, poly(A) ÷ RNA (10 p.g) from the indicated 
rat tissues was electrophoresed through a 1%o agarose gel under dena- 
turing conditions and transferred to a filter. The filter was hybridized 
to the mouse FXR-truncated cDNA that was ~P-labeled by the random 
primer method (Mangelsdorf et al., 1992) (5 x 10 s cpm/lig). This probe 
corresponds to rat FXR sequences spanning amino acids 1-297, 
which encode the amino terminus, the DBD, and a portion of the LBD 
of FXR. Hybridization was performed overnight at 65°C in 500 mM 
sodium phosphate (dibasic:monobasic, 7:3), 1 mM ethylenedi- 
aminetetracetic acid, 1% bovine serum albumin, and 7% SDS. The 
filter was washed twice in 2x  SSC (1 x SSC is 0.15 M NaCI, 0.015 
M sodium citrate) at room temperature and twice in 1 x SSC at 55°C 
and then autoradiographed with an intensifying screen at -70°C for 
5 days. In situ hybridizations were performed as described elsewhere 
(Bradley et al., 1994). 
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